OLMA
Olema Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.11
+8.05%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.77
From 52W high−80.16%
Volume1.27M
Market cap$622.11M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$6.77
From 52W high
−80.16%
Volume
1.27M
Market cap
$622.11M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
31.5
MomentumView details →
1D Return
+8.05%
YTD Return
−71.35%
SummaryUpdated Jun 1, 2026
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Francisco, California. Originally incorporated as CombiThera, Inc., the company changed its name to Olema Pharmaceuticals in March 2009 and went public in November 2020. Olema focuses exclusively on developing innovative therapies for women's cancers, particularly breast cancer, with its lead drug candidate currently in Phase 1/2 clinical trials.
Similar companies
Latest newsMore news →
Olema Pharmaceuticals appointed Prakash Raman to its Compensation Committee and Science and Technology Committee, effective October 15, 2026.4d agoOlema Pharmaceuticals director Gorjan Hrustanovic resigned from the board and its Compensation Committee and Science and Technology Committee, effective October 14, 2026.4d ago